Multiple meyloma
Conditions
Interventions
Sponsors
The Department of Hematology of the Affiliated Hospital of Southwest Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Aged 18 to 75 years, no gender limitations; 2.Relapsed or refractory to prior lenalidomide or/and bortezomib (either in combination or sequential)therapy (i.e. history of progression on therapy or within 60 days after completion); 3.Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2; 4.life expectancy of more than 3 months; 5.Total bilirubin <= 2.0mg/dL, and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 3 times the upper limit of normal; 6.Agree to sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Patients with known sensitivity to pomalidomide or bendamustine or dexamethasone and the accessories ; 2.Active treatment or intervention for other malignancy or need active treatment within 4 weeks of starting study treatment. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection; 3.Active hepatitis B virus infect, active hepatitis C infection, or known human immunodeficiency virus (HIV) positive; 4.Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure(NT-Pro-BNP>=1800pg/mL), unstable angina, or myocardial infarction within the past 6 months; 5.Infection requiring systemic antibiotic therapy or other serious infection; 6.Comorbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens. Psychiatric illness/social situation that would limit compliance with study requirements; 7.Under other clinical trial procedures; 8.Female patients who are lactating or pregnant; 9.Other patients not appropriate for the trial in the judgement of the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete remission and above remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival rate;Overall survival rate;MRD negative rate;Safety; | — |
Countries
China
Contacts
Public ContactXing Hongyun
The Affiliated Hospital of Southwest Medical University
Outcome results
None listed